Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

BACKGROUND: Changing the neoadjuvant chemotherapy regimen in insufficiently responding breast cancer is not a standard policy. We analysed a series of patients with ‘luminal'-type breast cancer in whom the second half of neoadjuvant chemotherapy was selected based on the response to the first h...

Descripción completa

Detalles Bibliográficos
Autores principales: Rigter, L S, Loo, C E, Linn, S C, Sonke, G S, van Werkhoven, E, Lips, E H, Warnars, H A, Doll, P K, Bruining, A, Mandjes, I A, Vrancken Peeters, M J, Wesseling, J, Gilhuijs, K G, Rodenhuis, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859944/
https://www.ncbi.nlm.nih.gov/pubmed/24149178
http://dx.doi.org/10.1038/bjc.2013.661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859944/
https://www.ncbi.nlm.nih.gov/pubmed/24149178
http://dx.doi.org/10.1038/bjc.2013.661

Ejemplares similares